IL-12-releasing nanoparticles for effective immunotherapy of metastatic ovarian cancer
Source abstract
Abstract
Abstract Immunotherapies such as immune checkpoint inhibitors are effective in treating several advanced cancers, but these treatments have had limited success in metastatic ovarian cancer. Here we engineered liposomal nanoparticles carrying a poly- ʟ -arginine/poly- ʟ -glutamate coating that promotes their binding and retention on the surface of ovarian cancer cells. Covalent anchoring of the potent immunostimulatory cytokine interleukin-12 (IL-12) to phospholipid headgroups of the liposome core enabled the polymer-coated particles to concentrate IL-12 in disseminated ovarian cancer tumours following intraperitoneal administration. Shedding of the layer-by-layer coating and serum-protein-mediated extraction of IL-12-conjugated lipids from the liposomal core over time enabled IL-12 to disseminate in the tumour bed following rapid nanoparticle localization in tumour nodules. Optimized IL-12-polymer-coated nanoparticles promoted robust T cell accumulation in ascites and tumours in mouse models, extending survival compared with free IL-12 and sensitizing tumours to immune checkpoint inhibitors, eliciting strong immune responses and immune memory. Overall, these findings support the potential of these polymer-coated nanoparticles for the sustained delivery of IL-12 to disseminated metastatic ovarian cancer.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (74)
Show source-provided references
1. Arora, T., Mullangi, S. & Lekkala, M. R. Ovarian Cancer (StatPearls Publishing, 2023).
2. Lheureux, S., Braunstein, M. & Oza, A. M. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J. Clin. 69, 280–304 (2019).10.3322/caac.21559 ↗
3. Esfahani, K. et al. A review of cancer immunotherapy: from the past, to the present, to the future. Curr. Oncol. 27, 87–97 (2020).10.3747/co.27.5223 ↗
4. Korman, A. J., Garrett-Thomson, S. C. & Lonberg, N. The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nat. Rev. Drug Discov. 21, 509–528 (2022).10.1038/s41573-021-00345-8 ↗
5. Upadhaya, S., Neftelinov, S. T., Hodge, J. & Campbell, J. Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape. Nat. Rev. Drug Discov. 21, 482–483 (2022).10.1038/d41573-022-00030-4 ↗
6. Chardin, L. & Leary, A. Immunotherapy in ovarian cancer: thinking beyond PD-1/PD-L1. Front. Oncol. 11, 795547 (2021).10.3389/fonc.2021.795547 ↗
7. Anderson, K. G., Stromnes, I. M. & Greenberg, P. D. Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. Cancer Cell 31, 311–325 (2017).10.1016/j.ccell.2017.02.008 ↗
8. Pires, I. S., Hammond, P. T. & Irvine, D. J. Engineering strategies for immunomodulatory cytokine therapies: challenges and clinical progress. Adv. Ther. 4, 2100035 (2021).10.1002/adtp.202100035 ↗
9. Agarwal, Y. et al. Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity. Nat. Biomed. Eng. 6, 129–143 (2022).10.1038/s41551-021-00831-9 ↗
10. Irvine, D. J. & Dane, E. L. Enhancing cancer immunotherapy with nanomedicine. Nat. Rev. Immunol. 20, 321–334 (2020).10.1038/s41577-019-0269-6 ↗
11. Yang, Y. et al. Nanomedicine strategies for heating ‘cold’ ovarian cancer (OC): next evolution in immunotherapy of OC. Adv. Sci. 9, 2105523 (2022).10.1002/advs.202202797 ↗
12. Thaker, P. H., Borys, N., Fewell, J. & Anwer, K. GEN-1 immunotherapy for the treatment of ovarian cancer. Future Oncol. 15, 421–438 (2019).10.2217/fon-2018-0423 ↗
13. Lin, Y. et al. Immunostimulatory gene therapy combined with checkpoint blockade reshapes tumor microenvironment and enhances ovarian cancer immunotherapy. Acta Pharm. Sin. B 14, 854–868 (2024).10.1016/j.apsb.2023.08.014 ↗
14. Wimalachandra, D. C. et al. Microfluidic-based immunomodulation of immune cells using upconversion nanoparticles in simulated blood vessel–tumor system. ACS Appl. Mater. Interfaces 11, 37513–37523 (2019).10.1021/acsami.9b15178 ↗
15. Mei, K.-C. et al. Liposomal delivery of mitoxantrone and a cholesteryl indoximod prodrug provides effective chemo-immunotherapy in multiple solid tumors. ACS Nano 14, 13343–13366 (2020).10.1021/acsnano.0c05194 ↗
16. Kang, Y. et al. Large, anionic liposomes enable targeted intraperitoneal delivery of a TLR 7/8 agonist to repolarize ovarian tumors’ microenvironment. Bioconjug. Chem. 32, 1581–1592 (2021).10.1021/acs.bioconjchem.1c00139 ↗
17. Correa, S. et al. Tuning nanoparticle interactions with ovarian cancer through layer-by-layer modification of surface chemistry. ACS Nano 14, 2224–2237 (2020).10.1021/acsnano.9b09213 ↗
18. Barberio, A. E. et al. Layer-by-layer interleukin-12 nanoparticles drive a safe and effective response in ovarian tumors. Bioeng Transl. Med. 7, e10453 (2022).
19. Barberio, A. E. et al. Cancer cell coating nanoparticles for optimal tumor-specific cytokine delivery. ACS Nano 14, 11238–11253 (2020).10.1021/acsnano.0c03109 ↗
20. Rüger, R., Müller, D., Fahr, A. & Kontermann, R. E. In vitro characterization of binding and stability of single-chain Fv Ni-NTA-liposomes. J. Drug Target 14, 576–582 (2006).10.1080/10611860600864018 ↗
21. Platt, V. et al. Influence of multivalent nitrilotriacetic acid lipid−ligand affinity on the circulation half-life in mice of a liposome-attached His6 -protein. Bioconjug. Chem. 21, 892–902 (2010).10.1021/bc900448f ↗
22. Ravasco, J. M. J. M., Faustino, H., Trindade, A. & Gois, P. M. P. Bioconjugation with maleimides: a useful tool for chemical biology. Chem. Eur. 25, 43–59 (2019).10.1002/chem.201803174 ↗
23. Correa, S., Boehnke, N., Deiss-Yehiely, E. & Hammond, P. T. Solution conditions tune and optimize loading of therapeutic polyelectrolytes into layer-by-layer functionalized liposomes. ACS Nano 13, 5623–5634 (2019).10.1021/acsnano.9b00792 ↗
24. Hashimoto, M., Niwa, O., Nitta, Y., Takeichi, M. & Yokoro, K. Unstable expression of E-cadherin adhesion molecules in metastatic ovarian tumor cells. Jpn J. Cancer Res. 80, 459–463 (1989).10.1111/j.1349-7006.1989.tb02336.x ↗
25. Pickering, A. J. et al. Layer-by-layer polymer functionalization improves nanoparticle penetration and glioblastoma targeting in the brain. ACS Nano 18, 4200–4216 (2024).10.1021/acsnano.4c02084 ↗
26. Tošić, I. et al. Lipidome-based targeting of STAT3-driven breast cancer cells using poly-ʟ-glutamic acid–coated layer-by-layer nanoparticles. Mol. Cancer Ther. 20, 726–738 (2021).10.1158/1535-7163.MCT-20-0505 ↗
27. Iwagoi, Y. et al. Omental metastasis as a predictive risk factor for unfavorable prognosis in patients with stage III–IV epithelial ovarian cancer. Int. J. Clin. Oncol. 26, 995–1004 (2021).10.1007/s10147-021-01866-3 ↗
28. Toyoshima, M. et al. Generation of a syngeneic mouse model to study the intraperitoneal dissemination of ovarian cancer with in vivo luciferase imaging. Luminescence 24, 324–331 (2009).10.1002/bio.1112 ↗
29. Nagao, S. et al. Intraperitoneal carboplatin for ovarian cancer—a phase 2/3 trial. N. Engl. J. Med. Evid. 2, EVIDoa2200225 (2023).
30. Leonard, J. P. et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90, 2541–2548 (1997).
31. Gokhale, M. S. et al. Single low-dose rHuIL-12 safely triggers multilineage hematopoietic and immune-mediated effects. Exp. Hematol. Oncol. 3, 11 (2014).10.1186/2162-3619-3-11 ↗
32. Eng, V. M. et al. The stimulatory effects of interleukin (IL)-12 on hematopoiesis are antagonized by IL-12-induced interferon gamma in vivo. J. Exp. Med. 181, 1893–1898 (1995).10.1084/jem.181.5.1893 ↗
33. Car, B. D. et al. Role of interferon-gamma in interleukin 12-induced pathology in mice. Am. J. Pathol. 147, 1693–1707 (1995).
34. Grigorian, A. & O’Brien, C. B. Hepatotoxicity secondary to chemotherapy. J. Clin. Transl. Hepatol. 2, 95–102 (2014).10.14218/JCTH.2014.00011 ↗
35. Gollob, J. A. et al. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J. Clin. Oncol. 21, 2564–2573 (2003).10.1200/JCO.2003.12.119 ↗
36. Orange, J. S., Wolf, S. F. & Biron, C. A. Effects of IL-12 on the response and susceptibility to experimental viral infections. J. Immunol. 152, 1253–1264 (1994).10.4049/jimmunol.152.3.1253 ↗
37. Mansurov, A. et al. Masking the immunotoxicity of interleukin-12 by fusing it with a domain of its receptor via a tumour-protease-cleavable linker. Nat. Biomed. Eng. 6, 819–829 (2022).10.1038/s41551-022-00888-0 ↗
38. Okła, K. Myeloid-derived suppressor cells (MDSCs) in ovarian cancer—looking back and forward. Cells 12, 1912 (2023).10.3390/cells12141912 ↗
39. Giuntoli, R. L. et al. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res. 29, 2875–2884 (2009).
40. Wirtz, K. W. A. Transfer of phospholipids between membrane. Biochim. Biophys. Acta Rev. Biomembr. 344, 95–117 (1974).10.1016/0304-4157(74)90001-X ↗
41. Abreu, M. S. C., Estronca, L. M. B. B., Moreno, M. J. & Vaz, W. L. C. Binding of a fluorescent lipid amphiphile to albumin and its transfer to lipid bilayer membranes. Biophys. J. 84, 386–399 (2003).10.1016/S0006-3495(03)74859-0 ↗
42. Doktorova, M. et al. Preparation of asymmetric phospholipid vesicles for use as cell membrane models. Nat. Protoc. 13, 2086–2101 (2018).10.1038/s41596-018-0033-6 ↗
43. Wolfbauer, G., Albers, J. J. & Oram, J. F. Phospholipid transfer protein enhances removal of cellular cholesterol and phospholipids by high-density lipoprotein apolipoproteins. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1439, 65–76 (1999).10.1016/S1388-1981(99)00077-3 ↗
44. Slater, S. J., Ho, C., Taddeo, F. J., Kelly, M. B. & Stubbs, C. D. Contribution of hydrogen bonding to lipid-lipid interactions in membranes and the role of lipid order: effects of cholesterol, increased phospholipid unsaturation, and ethanol. Biochemistry 32, 3714–3721 (1993).10.1021/bi00065a025 ↗
45. Zhu, X. et al. Surface de-PEGylation controls nanoparticle-mediated siRNA delivery in vitro and in vivo. Theranostics 7, 1990–2002 (2017).10.7150/thno.18136 ↗
46. Münter, R. et al. Dissociation of fluorescently labeled lipids from liposomes in biological environments challenges the interpretation of uptake studies. Nanoscale 10, 22720–22724 (2018).10.1039/C8NR07755J ↗
47. Chamie, K. et al. Final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC). J. Clin. Oncol. 40, 4508 (2022).10.1200/JCO.2022.40.16_suppl.4508 ↗
48. Santollani, L. et al. Local delivery of cell surface-targeted immunocytokines programs systemic antitumor immunity. Nat. Immunol. 25, 1820–1829 (2024).10.1038/s41590-024-01925-7 ↗
49. Knudson, K. M., Hodge, J. W., Schlom, J. & Gameiro, S. R. Rationale for IL-15 superagonists in cancer immunotherapy. Expert Opin. Biol. Ther. 20, 705–709 (2020).10.1080/14712598.2020.1738379 ↗
50. Hamanishi, J. et al. Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan (NINJA). J. Clin. Oncol. 39, 3671–3681 (2021).10.1200/JCO.21.00334 ↗
51. Zamarin, D. et al. Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG Oncology study. J. Clin. Oncol. 38, 1814–1823 (2020).10.1200/JCO.19.02059 ↗
52. Li, F. et al. The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: a systematic review and meta-analysis. EClinicalMedicine 41, 101134 (2021).10.1016/j.eclinm.2021.101134 ↗
53. Spranger, S. et al. Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci. Transl. Med. 5, 200ra116 (2013).10.1126/scitranslmed.3006504 ↗
54. Abiko, K. et al. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br. J. Cancer 112, 1501–1509 (2015).10.1038/bjc.2015.101 ↗
55. Wolf, Y., Anderson, A. C. & Kuchroo, V. K. TIM3 comes of age as an inhibitory receptor. Nat. Rev. Immunol. 20, 173–185 (2020).10.1038/s41577-019-0224-6 ↗
56. Sakuishi, K. et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207, 2187–2194 (2010).10.1084/jem.20100643 ↗
57. Simon, S. & Labarriere, N. PD-1 expression on tumor-specific T cells: friend or foe for immunotherapy? Oncoimmunology 7, e1364828 (2018).10.1080/2162402X.2017.1364828 ↗
58. Yang, Z.-Z. et al. IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J. Clin. Invest. 122, 1271–1282 (2012).10.1172/JCI59806 ↗
59. Lasek, W., Zagożdżon, R. & Jakobisiak, M. Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunol. Immunother. 63, 419–435 (2014).10.1007/s00262-014-1523-1 ↗
60. Roby, K. F. et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 21, 585–591 (2000).10.1093/carcin/21.4.585 ↗
61. Walton, J. et al. CRISPR/Cas9-mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian high-grade serous carcinoma. Cancer Res. 76, 6118–6129 (2016).10.1158/0008-5472.CAN-16-1272 ↗
62. Iyer, S. et al. Genetically defined syngeneic mouse models of ovarian cancer as tools for the discovery of combination immunotherapy. Cancer Discov. 11, 384–407 (2021).10.1158/2159-8290.CD-20-0818 ↗
63. Farokhi Boroujeni, S. et al. BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy. J. Ovarian Res. 16, 231 (2023).10.1186/s13048-023-01313-z ↗
64. Seitz, S. et al. CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer. Br. J. Cancer 126, 1470–1480 (2022).10.1038/s41416-022-01763-0 ↗
65. Rodriguez, G. M. et al. The tumor immune profile of murine ovarian cancer models: an essential tool for ovarian cancer immunotherapy research. Cancer Res. Commun. 2, 417–433 (2022).10.1158/2767-9764.CRC-22-0017 ↗
66. Martin, S. D. et al. Low mutation burden in ovarian cancer may limit the utility of neoantigen-targeted vaccines. PLoS ONE 11, e0155189 (2016).10.1371/journal.pone.0155189 ↗
67. Riley, R. S., June, C. H., Langer, R. & Mitchell, M. J. Delivery technologies for cancer immunotherapy. Nat. Rev. Drug Discov. 18, 175–196 (2019).10.1038/s41573-018-0006-z ↗
68. Wang, P. et al. Re-designing interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. Nat. Commun. 8, 1395 (2017).10.1038/s41467-017-01385-8 ↗
69. Moynihan, K. D. et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat. Med. 22, 1402–1410 (2016).10.1038/nm.4200 ↗
70. Liu, H. et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature 507, 519–522 (2014).10.1038/nature12978 ↗
71. Lieschke, G. J., Rao, P. K., Gately, M. K. & Mulligan, R. C. Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo. Nat. Biotechnol. 15, 35–40 (1997).10.1038/nbt0197-35 ↗
72. Han, K. et al. IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization. Cytokine 56, 804–810 (2011).10.1016/j.cyto.2011.09.028 ↗
73. Stewart, J. C. M. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal. Biochem. 104, 10–14 (1980).10.1016/0003-2697(80)90269-9 ↗
74. Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676–682 (2012).10.1038/nmeth.2019 ↗